USPTO Examiner STEADMAN DAVID J - Art Unit 1656

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19074055POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDESMarch 2025September 2025Allow610NoNo
19048328NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXINFebruary 2025December 2025Abandon1010NoNo
19048080NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXINFebruary 2025January 2026Abandon1120NoNo
18965675NOVEL CRISPR ENZYMES AND SYSTEMSDecember 2024January 2026Allow1421YesNo
18926774PHYLLOBACTERIUM MYRSINACEARUM STRAIN N1N2-2 FOR EFFICIENT DEGRADATION OF DIPHENYLARSINIC ACID AND USE THEREOFOctober 2024May 2025Allow621NoNo
18847017SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDESSeptember 2024February 2025Allow500YesNo
18666610Mannanase Variants and Polynucleotides Encoding SameMay 2024March 2026Allow2231YesNo
18693613METHOD FOR THE FERMENTATIVE PRODUCTION OF L-LYSINE USING C. GLUTAMICUM STRAINS EXPRESSING MODIFIED GLUCONATE REPRESSOR PROTEINS GNTR1 AND GNTR2March 2024December 2024Allow920YesNo
18601266METHODS OF MAKING CHITOSANMarch 2024September 2025Allow1800YesNo
18416306POLYMERASE ENZYME FROM PHAGE T4January 2024April 2025Abandon1501NoNo
18515603ENGINEERED POLYMERASES FOR IMPROVED SEQUENCING BY BINDINGNovember 2023August 2025Allow2121YesNo
18513744TARDIGRADE DISORDERED PROTEINS AS PROTEIN STABILIZERSNovember 2023February 2025Abandon1501NoNo
18476753NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITYSeptember 2023March 2025Allow1811YesNo
18471901OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USESeptember 2023June 2025Allow2010YesNo
18471524ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSSeptember 2023March 2025Allow1711YesNo
18464514DETERGENT COMPOSITIONS AND USES THEREOFSeptember 2023April 2025Abandon1921NoNo
18462921NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOFSeptember 2023September 2024Abandon1211NoNo
18455969GERANYLGERANYL PYROPHOSPHATE SYNTHASESAugust 2023June 2025Abandon2221YesNo
18454556METHOD FOR PRODUCING ETHANOL FROM LIGNOCELLULOSIC RAW MATERIALAugust 2023November 2025Allow5330YesNo
18348277Methods of Treating Fabric Using a Streptococcus HexosaminidaseJuly 2023May 2024Allow1001YesNo
18346420NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXINJuly 2023December 2023Allow510YesNo
18320389IN VITRO TRANSCRIPTION/TRANSLATION (TXTL) SYSTEM AND USE THEREOFMay 2023July 2024Abandon1401NoNo
18314979Platform for developing stable mammalian cell linesMay 2023November 2024Allow1811YesNo
18313195METHOD FOR INCREASING YIELD OF 7-DEHYDROCHOLESTEROL IN YEAST BY USING COMPARTMENTALIZATIONMay 2023November 2025Abandon3041NoNo
18299479REDUCED GENOME E. COLI LACKING TOXIN-ANTITOXIN GENESApril 2023March 2024Allow1111NoNo
18127674METHOD FOR PREPARING AN ANTIMYCIN COMPOUND PRODUCED BY STREPTOMYCES SP.4-7March 2023October 2023Allow710NoNo
18183191L-GLUTAMATE DEHYDROGENASE MUTANT AND APPLICATION THEREOFMarch 2023May 2024Abandon1401NoNo
18044250ESTERASE AND METHODS OF USE, THEREOFMarch 2023March 2026Allow3611YesNo
18172517METHOD FOR TREATING A TISSUE DEFECT WITH A COLLAGEN-CONTAINING MEMBRANEFebruary 2023November 2024Allow2110NoNo
18159745PROCESSES AND SYSTEMS FOR CATALYTIC MANUFACTURE OF WAX ESTER DERIVATIVESJanuary 2023January 2024Allow1120YesNo
18159735PROCESSES AND SYSTEMS FOR CATALYTIC MANUFACTURE OF WAX ESTER DERIVATIVESJanuary 2023August 2024Allow1830NoNo
18157512ENGINEERED GLUCOSYLTRANSFERASESJanuary 2023August 2024Allow1911NoNo
18084888NOVEL NADH-DEPENDENT ENZYME MUTANTS TO CONVERT ACETONE INTO ISOPROPANOLDecember 2022February 2024Allow1410YesNo
18061840CONVERSION OF LIGNIN INTO BIOPLASTICS AND LIPID FUELSDecember 2022December 2024Allow2511YesNo
18057800METHODS OF RECOMBINANTLY PRODUCING NEUTRAL PROTEASE ORIGINATING FROM PAENIBACILLUS POLYMXANovember 2022October 2024Allow2311NoNo
18057854TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDESNovember 2022January 2025Abandon2621NoNo
18053614PolypeptidesNovember 2022July 2024Allow2000YesNo
17972132Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3October 2022March 2025Abandon2921NoNo
17996202RECOMBINANT FUSION PROTEIN FOR PREVENTING OR TREATING FIBROTIC DISEASESOctober 2022January 2026Abandon3901NoNo
18045573DETERGENT COMPOSITIONS AND USES THEREOFOctober 2022April 2024Abandon1811YesNo
17916652THERMOSTABLE PHYTASE FOR LOW SODIUM STARCH LIQUEFACTIONOctober 2022February 2026Abandon4010NoNo
17913678BIOFILM ENHANCED TEXTILE AND METHODS FOR MANUFACTURING THEREOFSeptember 2022January 2026Abandon4001NoNo
17931214De novo designed rotor (axle:ring) protein assembliesSeptember 2022February 2026Abandon4101NoNo
17930761POLYNUCLEOTIDES ENCODING APOA1-RNASE FUSION POLYPEPTIDESSeptember 2022December 2024Abandon2711NoNo
17941373GENETICALLY ENGINEERED VIBRIO SP. AND USES THEREOFSeptember 2022March 2025Allow3031YesNo
17930203Polypeptides having Xylanase Activity and Polynucleotides Encoding SameSeptember 2022September 2024Allow2450NoNo
17801644SYNTHESIS OF C-GLYCOSIDES OF INTERESTAugust 2022July 2025Abandon3401NoNo
17820155CNS DELIVERY OF THERAPEUTIC AGENTSAugust 2022May 2025Allow3331NoNo
17887538STRAIN OF PSEUDOMONAS AERUGINOSA 9# AND APPLICATIONS THEREOFAugust 2022August 2024Abandon2420NoNo
17799016MANNANASE VARIANTSAugust 2022September 2025Allow3821YesNo
17798973MANNANASE VARIANTSAugust 2022October 2025Allow3821YesNo
17796500MANNANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEJuly 2022September 2025Allow3821YesNo
17814371HUMAN ALPHA-GALACTOSIDASE VARIANTSJuly 2022May 2024Allow2121NoNo
17791566METHOD FOR PREPARING SOY LEGHEMOGLOBIN USING ESCHERICHIA COLIJuly 2022December 2025Abandon4101NoNo
17757734METHOD OF PURIFYING BOTUFINUM TOXINJune 2022May 2025Allow3511YesNo
17751200TRANSAMINASE REACTIONSMay 2022October 2024Allow2931NoNo
17749857METHOD FOR PRODUCING USEFUL SUBSTANCEMay 2022December 2025Abandon4321NoNo
17745205BETA-LACTAMASE VARIANTSMay 2022March 2024Abandon2220NoNo
17739028ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSMay 2022June 2023Allow1411YesNo
17772820STRAIN WITH IMPROVED AROMATIC AMINO ACID PRODUCTION CAPACITY BY ANSB GENE INACTIVATIONApril 2022February 2024Abandon2211NoNo
17728812FLUORESCENCE-BASED REPORTERS FOR MUTAGENESIS DETECTION IN E. COLIApril 2022August 2023Allow1521YesNo
17698397ASSAY FOR DETERMINING TARGET ENGAGEMENT IN REAL-TIME IN LIVING SYSTEMSMarch 2022February 2026Abandon4741NoNo
17638822CRM197 PROTEIN EXPRESSION METHODFebruary 2022October 2025Allow4411YesNo
17638596BIOSYNTHETIC METHODS FOR THE PRODUCTION OF L-4-CHLOROKYNURENINEFebruary 2022January 2026Abandon4741NoNo
17672542NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITYFebruary 2022June 2023Allow1611YesNo
17667379ENGINEERED POLYMERASES FOR IMPROVED SEQUENCING BY BINDINGFebruary 2022September 2023Allow1921NoNo
17586772ENZYMATIC CIRCUITS FOR MOLECULAR SENSORSJanuary 2022October 2025Abandon4401NoNo
17621052A Chemo-Enzymatic Process for the Preparation of Homopropargylic AlcoholDecember 2021December 2024Allow3611NoNo
17620654RARE EARTH ELEMENT (REE)-BINDING PROTEINSDecember 2021September 2025Abandon4501NoNo
17554128NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXINDecember 2021October 2025Abandon4651YesNo
17547429METHODS AND COMPOSITIONS FOR IMPROVED PRODUCTION OF AN ANTIGEN FOR USE IN AN S. AUREUS VACCINEDecember 2021December 2023Abandon2401NoNo
17596281CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATIONDecember 2021March 2026Abandon5121NoNo
17541565GERANYLGERANYL PYROPHOSPHATE SYNTHASESDecember 2021May 2023Allow1811YesNo
17456166Processes and Systems for Catalytic Manufacture of Wax Ester DerivativesNovember 2021January 2026Allow4921YesNo
17527429MODIFIED STRAINS FOR THE PRODUCTION OF RECOMBINANT SILKNovember 2021February 2026Allow5111YesNo
17520849ENZYMES AND METHODS FOR PREVENTING AND TREATING PYRETHROID EXPOSURE IN ANIMALSNovember 2021November 2023Abandon2421YesNo
17520714ENTEROBACTER CHENGDUENSIS FOR PRODUCING NICOTINAMIDE MONONUCLEOTIDE AND APPLICATION THEREOFNovember 2021October 2022Abandon1111NoNo
17453306MODIFIED CHLORAMPHENICOL ACETYLTRANSFERASE AND BIOSYNTHESIS METHOD OF MAKING ESTERS USING SAMENovember 2021December 2024Abandon3741YesNo
17506676Preparation and Application of Soluble Tim-3 Recombinant Protein and Mutant Protein ThereofOctober 2021May 2025Abandon4301NoNo
17505060METHOD FOR DEGRADING BENZO(A)PYRENE WITH A HALOPHILIC BACTERIUM STRAIN OF STAPHYLOCOCCUS HAEMOLITICUSOctober 2021July 2025Abandon4521YesYes
17604623A NITRILASE MUTANT AND APPLICATION THEREOF IN THE SYNTHESIS OF AN ANTI-EPILEPTIC DRUG INTERMEDIATEOctober 2021January 2024Allow2721YesNo
17491845Lysin Agent and Method of Use for Diagnostic TestingOctober 2021November 2023Abandon2621NoNo
17600345ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSSeptember 2021March 2024Allow3011YesNo
17599696METHOD OF PREPARING TOXINSeptember 2021October 2024Allow3640NoNo
17442459NOVEL BIFIDOBACTERIUM GENUS BACTERIUM HAVING HIGH CAPACITY TO UTILIZE POLYSACCHARIDES OF DIETARY ORIGINSeptember 2021March 2025Allow4230YesNo
17462849HYDROGEL COMPOSITION, MANUFACTURING METHOD THEREOF AND ENZYMATICALLY FORMED HYDROGEL COMPOSITIONAugust 2021October 2024Abandon3821NoNo
17407892SESQUITERPENE SYNTHASES FOR PRODUCTION OF DRIMENOL AND MIXTURES THEREOFAugust 2021April 2023Allow2020YesNo
17405012RECOMBINANT PROTEINS HAVING ENZYME ACTIVITY AGAINST MICROCYSTIN AND METHODS OF WATER REMEDIATIONAugust 2021June 2024Abandon3421NoNo
17427171Method of Making 2-Oxygenated Decalins From Isoprenoids Using a Squalene-Hopene CyclaseJuly 2021January 2024Allow3011YesNo
17386106AN EXPRESSION VECTOR ENCODING A PAENIBACILLUS POLYMXA NEUTRAL PROTEASEJuly 2021August 2022Allow1320NoNo
17415856SINGLE STEP BIOCATALYTIC AMIDATIONJune 2021October 2024Allow4041NoNo
17350909TREATMENT OF SANFILIPPO SYNDROME TYPE BJune 2021February 2025Abandon4432NoNo
17348363YEAST CELLS HAVING REDUCTIVE TCA PATHWAY FROM PYRUVATE TO SUCCINATE AND OVEREXPRESSING AN EXOGENOUS NAD(P+) TRANSHYDROGENASE ENZYMEJune 2021March 2023Allow2111YesNo
17337613Lipolytic Enzyme for Use in BakingJune 2021September 2022Allow1500YesNo
17297606REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTIONMay 2021August 2024Abandon3901NoNo
17332459OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USEMay 2021September 2024Allow4071YesNo
17327319ENHANCEMENT OF KINASE TARGET ENGAGEMENTMay 2021October 2024Abandon4021NoNo
17317812BREVIBACILLUS AGRI, PREPARATION THEREOF, METHOD FOR PREPARING SURFACTANT AND USE THEREOFMay 2021November 2023Allow3021NoNo
17289946GENETICALLY ENCODED FLUORESCENT INDICATORS UNDER OPTOGENETIC CONTROL AND USES THEREOFApril 2021December 2025Allow5631YesNo
17239325RECOMBINANT COMPONENTS AND COMPOSITIONS FOR USE IN FOOD PRODUCTSApril 2021January 2024Allow3341YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEADMAN, DAVID J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
32
Examiner Affirmed
28
(87.5%)
Examiner Reversed
4
(12.5%)
Reversal Percentile
24.7%
Lower than average

What This Means

With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
155
Allowed After Appeal Filing
17
(11.0%)
Not Allowed After Appeal Filing
138
(89.0%)
Filing Benefit Percentile
14.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 11.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner STEADMAN, DAVID J - Prosecution Strategy Guide

Executive Summary

Examiner STEADMAN, DAVID J works in Art Unit 1656 and has examined 1,210 patent applications in our dataset. With an allowance rate of 49.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner STEADMAN, DAVID J's allowance rate of 49.6% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by STEADMAN, DAVID J receive 2.25 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STEADMAN, DAVID J is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +36.6% benefit to allowance rate for applications examined by STEADMAN, DAVID J. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.5% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.1% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 63.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 69.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.5% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.0% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.0% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.